In a proud moment for the organization and the Indian pharmaceutical sector at large, Dycine Pharma has been honored with the “Best Pharma Innovator 2025” award at the prestigious Global Pharma Excellence Summit, held in Geneva this year. The award recognizes Dycine’s trailblazing efforts in pharmaceutical innovation, R&D advancements, and industry leadership in shaping the future of healthcare.
The event brought together global leaders, researchers, policymakers, and pioneers in pharmaceutical manufacturing, with over 200 companies competing across various categories. Dycine stood out for its impressive strides in drug delivery technologies, sustainable formulations, and digital transformation across its operations.
“This award is a validation of our relentless commitment to innovation, patient-centric solutions, and scientific excellence,” said Dr. Neha Sinha, Director of Innovation & Strategy at Dycine Pharma. “We believe that the future of pharma lies in agile research, ethical manufacturing, and putting people before profits.”
The award jury, comprising internationally acclaimed healthcare experts and regulatory bodies, highlighted Dycine’s recent breakthroughs in extended-release oral formulations, eco-friendly packaging innovations, and the integration of AI in quality control and supply chain optimization. These contributions were cited as exemplary models of how pharmaceutical companies can drive impact beyond the lab.
Over the past year, Dycine has expanded its research pipeline across chronic disease therapeutics, launched a new sustainable packaging unit, and collaborated with global institutions on public health initiatives. The company’s continued investment in green chemistry and digital compliance tools also reflects its vision to lead not just in products, but in purpose.
“Innovation isn’t just about new molecules or machines. It’s about a mindset—one that questions norms, challenges limitations, and designs better outcomes for all,” said Mr. Praveen Mahale, CEO of Dycine Pharma. “This recognition belongs to our entire team who work tirelessly to turn bold ideas into better health.”
The “Best Pharma Innovator” award is expected to further strengthen Dycine’s presence in international markets and attract new strategic partnerships, particularly in the areas of biologics, rare diseases, and precision medicine. With new facilities planned in Asia and Europe, and a strong innovation pipeline through 2026, Dycine is positioning itself as a forward-looking force in global healthcare.
This accolade is more than a milestone—it’s momentum. And Dycine Pharma is just getting started.
